Neurogene Inc. (NGNE) — Stock Score Summary

Neurogene Inc. (NGNE) has a MoatMap StockRank of 42/100 based on Quality (34/100), Value (40/100), and Momentum (55/100) factor scores. The current signal is HOLD.

Neurogene Inc. is a clinical-stage biotechnology company pioneering gene therapies for patients with rare neurological diseases. The company leverages its proprietary gene therapy platform and deep scientific expertise to develop transformative treatments, aiming to address the underlying genetic causes of devastating neurological conditions.

Key Financial Metrics

Price$27.50
Market Cap$435M
P/E (Forward)-4.85
Price/Book1.58
Return on Equity-37.3%
Return on Invested Capital-33.2%
Debt/Equity3.84
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-48M

Neurogene Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Neurogene Inc.’s (NGNE) StockRank?
MoatMap’s StockRank for Neurogene Inc. (NGNE) is 42/100, with a Hold signal. It is a composite of Quality (34), Value (40), and Momentum (55) factor ranks across MoatMap’s 19,000+ stock universe.
Does Neurogene Inc. have an economic moat?
Neurogene Inc. (NGNE) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Neurogene Inc. a buy, hold, or sell?
MoatMap’s current signal for Neurogene Inc. (NGNE) is Hold, based on a StockRank of 42/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Neurogene Inc. in?
Neurogene Inc. (NGNE) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksNGNE deep dive reportAI ChampionsHow we score stocksSense-check another stock